Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (415)	9/30/2002 12:57:30 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1022

Again..... why aren't more antibodies described, from academic collaborators, in the literature? XenoMouse or HuMab, a search comes up with few recent successes. And those involve bacteria, bacterial toxins, and HIV. As I've been saying, I'd go with CATG and clones. If you're trying to produce anything anti-human, there are very simple serology lessons that scream "avoid MEDX and ABGX". Beyond that, the record still doesn't look, IMO, that impressive. That's the part that worries me.